Sensorion prepares US listing and files with the SEC
The French biotech company has filed a draft registration document with the American regulator, the first formality of a potential listing on the other side of the Atlantic.
Sensorion (FR001401A9Z0 - ALSEN), a clinical-stage biotechnology company specializing in the development of therapies to restore hearing and treat hearing loss disorders, announced on September 16, 2026 that it has confidentially submitted a draft registration document on Form F-1 to the Securities and Exchange Commission (SEC), the regulator of American financial markets.
This confidential submission constitutes a preliminary step in the company's evaluation of a possible initial public offering in the United States of its ordinary shares.
An ADS listing being considered, subject to market conditions
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The contemplated transaction could take the form of American Depositary Shares (ADS) and result in a listing of these ADS on a US national marketplace, subject to market conditions and other conditions.
The company specifies that this press release does not constitute an offer to sell or a solicitation to buy securities and that it is being disseminated in compliance with Rule 135 of the Securities Act of 1933.
Related
SectorPharmacie et biotechnologies›Biotechnologies
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Net income: -20,7 millions d'euros
Guidance from the release
« Sur la base de sa trésorerie, de ses équivalents de trésorerie et de ses dépôts à court terme classés en actifs courants au 30 juin 2026, la Société estime être en mesure de financer ses activités jusqu'à la fin de l'année 2027. » ; « la Société a informé son comité d'entreprise d'un projet de restructuration organisationnelle … n'est pas en mesure, à ce stade, d'en estimer l'impact financier »
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
